Arun Jesudian, MD

Medical experts share insights on managing refractory hepatic encephalopathy and provide concluding remarks and essential points on the condition.

The group of hepatic encephalopathy (HE) professionals acknowledges the challenges and potential overwhelm faced by busy primary care practices when managing patients with HE, and they provide practical clinical pearls and advice to support these clinicians in delivering effective care and improving patient outcomes.

Medical experts discuss the management of patients with hepatic encephalopathy (HE) receiving lactulose and rifaximin therapy and develop diarrhea or a urinary tract infection (UTI) in the outpatient setting.

The expert panel on hepatic encephalopathy (HE) presents clinical recommendations for managing patients with recurrent or episodic HE in the outpatient setting.

The panel reviews the current American Association for the Study of Liver Diseases (AASLD) guideline recommendations for treating patients with hepatic encephalopathy (HE), and they also discuss the role of rifaximin, its ability to be prescribed by primary care clinicians, and its safety profile.

Nancy Reau, MD, leads a discussion on the current abnormality-targeting agents used to prevent and treat hepatic encephalopathy (HE) by addressing the gut-liver axis, specifically focusing on lactulose or lactitol and rifaximin, while also explaining their mechanisms of action and adverse event profiles.

Kimberly Brown, MD, explains the role of the gut microbiota in the development of hepatic encephalopathy (HE) and describes the common alterations to the microbiota that occur because of chronic liver disease.

Arun B. Jesudian, MD, discusses strategies to prevent the progression of cirrhosis, which include targeting microbiome abnormalities to improve the gut-liver axis, enhancing circulatory function, treating the inflammatory state, and addressing portal hypertension.

The panel examines the evolving role of primary care clinicians in managing patients with hepatic encephalopathy (HE) and emphasizes the importance of consulting specialists when necessary, providing insights from the perspective of a primary care clinician.

The expert panelists explore the symptoms and risk factors associated with HE, the challenges in diagnosing the condition due to its resemblance to neuropsychiatric l disorders, and the methods used to assess and grade the severity of the disease.

Medical experts emphasize the importance of educating primary care clinicians about the outpatient management of hepatic encephalopathy, a common complication of portal hypertension, and highlight the crucial role of ammonia testing in effectively managing the disease.

Pamela Kushner, MD, FAAFP; Nancy Reau, MD; Arun B. Jesudian, MD, and Kimberly Brown, MD, discuss the impact of hepatic encephalopathy (HE) on patients and their families, as well as strategies for improving patient outcomes.

Hepatology experts discuss educating patients with hepatic encephalopathy on managing medications and supplements.

Kimberly A. Brown, MD, shares approaches to educating patients on management of hepatic encephalopathy and the importance of medication adherence and nutrition.

Drs Arun Jesudian and James William discuss approaches for proper discharge planning and transition of care and how this can reduce readmission for patients with hepatic encephalopathy.

A transplant hepatologist shares advice for emergency department physicians and clinicians to improve the diagnosis and treatment of hepatic encephalopathy.

Expert hepatologists comment on primary care providers using rifaximin to manage and prevent episodes of hepatic encephalopathy.

Arun B. Jesudian, MD, and Kimberly A. Brown, MD, highlight clinical trial data of rifaximin for the treatment of hepatic encephalopathy.

James Williams, MS, DO, FACEP, provides insight on the importance of medication reconciliation when managing patients with hepatic encephalopathy.

Arun Jesudian, MD, and James Williams, MS, DO, FACEP, highlight precipitating factors for HE and medication compliance for the condition.

Kimberly A. Brown, MD, reviews the use of lactulose and rifaximin as first-line treatment of hepatic encephalopathy.

Arun B. Jesudian, MD, and Kimberly A. Brown, MD, discuss conditions that may be mistaken for hepatic encephalopathy.

An expert in emergency medicine and a transplant hepatologist consider common infections that patients with hepatic encephalopathy should be evaluated for.

Drs Arun Jesudian and James Williams discuss treatment with lactulose and rifaximin for patients with hepatic encephalopathy and clinical data on their effect on hospital length of stay.

Experts in hepatology comment on effectiveness of diagnostic testing hepatic encephalopathy.

Expert hepatologists discuss how to identify patients with hepatic encephalopathy who require hospitalization vs outpatient care.

James Williams, MS, DO, FACEP, comments on current treatment options and treatment selection for hepatic encephalopathy.

Arun Jesudian, MD, and James Williams, MS, DO, FACEP, review the AASLD and EASL guideline approaches to the management of overt hepatic encephalopathy (HE) and comment on the grading of HE based on presentation.

Kimberly A. Brown, MD, comments on the life-threatening nature of recurrent HE and how to navigate patient conversations.

Experts in hepatology discuss the pathophysiology of HE and how certain factors influence the brain in HE.